Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. [electronic resource]
Producer: 20010322Description: 571-8 p. digitalISSN:- 0022-1899
- Adult
- Aged
- Anti-HIV Agents -- administration & dosage
- CD4 Lymphocyte Count
- Dideoxynucleosides -- administration & dosage
- Drug Therapy, Combination
- Female
- HIV Infections -- drug therapy
- HIV-1 -- genetics
- Humans
- Lamivudine -- administration & dosage
- Male
- Middle Aged
- RNA, Viral -- blood
- Reverse Transcriptase Inhibitors -- therapeutic use
- Treatment Outcome
- Viral Load
- Zidovudine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.